WEHI-3773
Based on 1 Customer Validation
WEHI-3773 is a VDAC2 ligand and apoptosis modulator. WEHI-3773 directly binds to the β7-β10 region of VDAC2 and disrupts its interaction with BAX and BAK. WEHI-3773 regulates BAX-mediated apoptosis in BAK-deficient cells by modulating conformational activation of BAX, mitochondrial redistribution, and cytochrome c release. WEHI-3773 overcomes Venetoclax (HY-15531) resistance, resensitizes leukemia cells carrying BAX mutations to BH3 mimetics, and enables long-term clonogenic survival of BAK-deficient cells treated with BH3 mimetics. WEHI-3773 is applicable to research related to acute myeloid leukemia.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C30H22N10O2S2
- Molecular Weight:618.69
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biologische Aktivität
Beschreibung
IC50 & Target
|
VDAC2 |
Bax |
Bak |
In Vitro
WEHI-3773 inhibits BAX-mediated apoptosis in BAK-deficient cells by blocking the conformational activation, mitochondrial redistribution and cytochrome c release of BAX. In BAX-deficient cells, WEHI-3773 promotes BAK-mediated apoptosis by inducing the conformational activation of BAK, cytochrome c release and VDAC2 dissociation[1].
WEHI-3773 (0.1-10000 nM; pre-incubated for 2 h followed by co-incubation with BH3 mimetics for 22 h) dose-dependently enhances BAK-mediated apoptosis in Bax-/- Vdac2-/- mouse embryonic fibroblasts (MEFs) expressing VDAC2 or a chimeric VDAC protein containing the β7 to β10 region of VDAC2, but exerts no such effect in cells expressing VDAC1 or a chimeric protein lacking this region[1].
WEHI-3773 (200 nM; 48 h) enhances BH3 mimetic-induced cell death in BAX-/- MV4;11 acute myeloid leukemia (AML) cells and reverses venetoclax resistance caused by BAX deletion[1].
WEHI-3773 (200 nM; 48 h) enhances BH3 mimetic-induced cell death in venetoclax-resistant OCI-AML3 acute myeloid leukemia cells harboring BAX mutations, thereby overcoming acquired venetoclax resistance[1].
WEHI-3773 (80-10000 nM) dose-dependently promotes BAK conformational activation and cytochrome c release in BAK-/- HeLa cells treated with ABT-737 + S63845[2].
WEHI-3773 (200 nM; 48 h) restores the sensitivity of BAX-/- MV4;11 human acute myeloid leukemia (AML) cells to venetoclax, S63845, and their combination following 48 h of co-treatment[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Bax-/- Vdac2-/- mouse embryonic fibroblasts (MEFs) expressing VDAC1/VDAC2 chimeric proteins, full-length VDAC1, or full-length VDAC2
-
Concentration:0.1-10000 nM
-
Incubation Time:2 h pre-incubation, followed by 22 h incubation with BH3 mimetics
-
Result:Reduced cell viability dose-dependently in cells expressing full-length VDAC2, VDAC1/2-a, or VDAC1/2-c chimeric proteins. Reduced viability in cells expressing VDAC1/2-d chimeric proteins, but to a lesser extent at higher concentrations. Had no effect on viability in cells expressing full-length VDAC1 or VDAC1/2-b chimeric proteins.
-
Cell Line:BAX-/- MV4;11 human acute myeloid leukemia (AML) cells
-
Concentration:200 nM
-
Incubation Time:48 h
-
Result:Significantly sensitized cells to cell death induced by venetoclax, S63845, or the combination of venetoclax and S63845, with statistically significant reductions in cell viability observed across multiple concentrations of each BH3 mimetic treatment.
-
Cell Line:BAX-mutant OCI-AML3 human acute myeloid leukemia (AML) cells resistant to venetoclax (BCL-2i R)
-
Concentration:200 nM
-
Incubation Time:48 h
-
Result:Significantly sensitized cells to cell death induced by venetoclax, S63845, or the combination of venetoclax and S63845, with statistically significant reductions in cell viability observed across multiple concentrations of each BH3 mimetic treatment.
Significantly sensitized cells to cell death induced by BH3 mimetics.
-
Cell Line:BAX-/- MV4;11 human acute myeloid leukemia (AML) cells
-
Concentration:200 nM (combined with serial dilutions of venetoclax, S63845, or venetoclax + S63845)
-
Incubation Time:48 h
-
Result:Significantly sensitized cells to cell death induced by venetoclax, S63845, and the combination of venetoclax + S63845.
Significantly sensitized cells to cell death induced by venetoclax, S63845, and the combination of venetoclax + S63845.
Chemical Information
-
Appearance Solid
-
Molecular Weight 618.69
-
Formel C30H22N10O2S2
-
Color Brown to red
-
SMILES
CSC1=CC=C(N2C(/C(C3=C(N)C(C#N)=C(N)N=C32)=C4C(N(C5=CC=C(SC)C=C5)C6=NC(N)=C(C#N)C(N)=C6/4)=O)=O)C=C1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Protokoll
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
Reinheit & Dokumentation
-
Data Sheet (280 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)